Hanny Al-samkari MD

Dr. Hanny Al-Samkari is the Peggy S. Blitz Endowed Chair in Hematology/Oncology at the Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. He is a classical hematologist and NIH-funded clinical investigator and serves as the Co-Director of the MGH Hereditary Hemorrhagic Telangiectasia (HHT) Center of Excellence. His clinical and research interests are in hemostasis, thrombosis, and hemolysis, with focuses in HHT, immune thrombocytopenia, and hemolytic anemias. Additionally, Dr. Al-Samkari cares for patients with hematologic complications of cancer, including chemotherapy-induced thrombocytopenia. As a clinical investigator, Dr. Al-Samkari is an internationally recognized expert in the clinical development of novel therapeutics for these disorders and serves as the principal investigator for many clinical trials, allowing him to offer new and promising treatment options to patients with these disorders.

Dr. Al-Samkari received his medical degree from Washington University in St. Louis, completed his residency in internal medicine at the Hospital of the University of Pennsylvania (where he also served as Chief Medical Resident), and completed his fellowship in hematology and medical oncology at the Dana-Farber Cancer Institute-Massachusetts General Hospital combined program.

In his role as Co-Director of the MGH Hereditary Hemorrhagic Telangiectasia Center of Excellence, Dr. Al-Samkari cares for several hundred patients with HHT and has clinics dedicated to the care of patients with HHT. Patients with HHT seeking care at our internationally recognized center are encouraged to schedule an appointment with Dr. Al-Samkari.